Attacking Devastating Diseases
With Breakthrough Science
Neuroscience
Martin Mackay, Ph.D.
Senior Vice President
Worldwide Research and Technology
Valid as of November 30, 2006
Neuroscience Vision
We will Change Society
by Lifting the Burden of
Neuropsychiatric Disease
Valid as of November 30, 2006
Progress in Our Lifetimes
Strategy in Brief
‹
Alzheimer’s Disease – Fully Exploit
Scientific Breakthroughs
‹
Cognition and ADHD – Increased Effort Builds
Upon Internal Discoveries
‹
Bipolar Disorder and Schizophrenia – Advance
Several Programs Into The Clinic
‹
Depression and Anxiety – Leverage New Science
to Discover Novel Targets
‹
Sleep Quality – Mine the α 2δ Advances
Valid as of November 30, 2006
A Substantial And Broad Program
Preclinical
Phase 1
27 Candidates for Schizophrenia,
ADDM, ADHD, Anxiety,
Depression and Pain
2 Candidates for ADDM (Aβ
(Aβ & RAGE mAb
mAb))
7 Candidates for Schizophrenia,
Depression & Pain
SSRI/5HT1b for Depression
Phase 2
Alpha 2 Delta for GAD; Alpha 2 Delta
for Insomnia; RAGE for ADDM
mAb for Pain; PGE2/EP4 for OA;
NRI for NeP/Fibromyalgia
Phase 3
Lyrica for Fibromyalgia
Valid as of November 30, 2006
Key Programs
‹
Lyrica for Fibromyalgia*
‹
S,S--Reboxetine for Neuropathic Pain*
S,S
‹
α 2δ Platform*
‹
Alzheimer’’ s Disease
Alzheimer
y RN1219 - Rinat
y TTP488/TTP4000 - TransTech
‹
Schizophrenia
y PDE
PDE--10 Inhibitor
*Indicates First-Time Disclosure By Pfizer Today
Valid as of November 30, 2006
Lyrica
A Breakthrough for Fibromyalgia
Clinical Features
‹
Chronic, Widespread Pain
‹
Decreased Pain Threshold
‹
Several CoCo
- Morbidities
Co-Morbidities
(e.g., Sleep, Fatigue, Anxiety)
High Medical Need
‹
‹
Prevalent, Poorly Diagnosed,
and Badly Managed Condition
No Approved Medicines
Valid as of November 30, 2006
New Data – Just Released
Lyrica (mg/day)
Mean Change from Baseline
Pl acebo (n=1 29)
1 50 (n= 131)
300 (n=1 32)
450 (n=128 )
0.0
-0.5
-1.0
Sustained Efficacy in
Fibromyalgia Patients
-1.5
-2.0
-2.5
p=0.0009
-3.0
Valid as of November 30, 2006
S,S-Reboxetine
Neuropathic Pain
‹
Chronic, Non-Malignant
Pain Where the Central
Nervous System is
Malfunctioning
‹
S,S-Reboxetine is a Highly
Selective Norepinephrine
Reuptake Inhibitor (NRI)
‹
Controlled-Release
Formulation for
Once-Daily Administration
Valid as of November 30, 2006
Pain Relief in Treatment Failures
Placebo
Weekly Average Pain Score
7
S,S-Reboxetine
6
5
4
0
1
2
3
4
5
Time (Weeks)
Valid as of November 30, 2006
A Thriving α 2δ Portfolio
Anxiety
Sleep
‹
‹
PD-332,334
‹
‹
Lyrica
‹
‹
PD-200,390
Neuroscience
α
2δ
α2δ
Hot Flashes
‹
‹
PD-299,685
Women’s Health
Neuropathic
Pain
‹
‹
PF-293,765
‹
‹
PF-2,393,296
‹
‹
Lyrica
Pain
Valid as of November 30, 2006
PD-332,334
Impressive Results in Anxiety
48%
Responder Rates (%)
50%
38%
40%
29%
30%
31%
26%
Placebo
PD--332,334 250mg BID
PD
XanaxXR 1mg BID
20%
13%
10%
0%
Week 1
Week 4
% of Patients Greater Than or
Equal to 50% Reduction HAMHAM-A
Valid as of November 30, 2006
PD-200,390
A Breakthrough for Sleep Quality
‹
Insomnia Impacts 50%
of General Population
‹
10% of General
Population Suffer from
Poor Sleep Quality
‹
Program Covers
Insomnia and
Sleep Quality
Valid as of November 30, 2006
PD-200,390
Total Sleep Time
440
Mean Total Sleep Time (min)
Placebo
420
PD
PD-200,390
PD-200,390
Zolpidem
400
380
360
340
Placebo
PD--200,390
PD
Zolpidem
Valid as of November 30, 2006
PD-200,390
Number of Awakenings
Mean Number of Awakenings
10
Placebo
PD
PD-200,390
PD-200,390
8
Zolpidem
6
4
2
0
Placebo
PD--200,390
PD
Zolpidem
Valid as of November 30, 2006